Although the intravitreal injection of anti-VEGF is an effective treatment option in the prevention of vision loss or improvement of vision in patients with CNV [2], it is relatively expensive and has been shown to result in various complications, including endophthalmitis, cataracts, retinal artery occlusion, or other complications [13–15]. Here, VEGFA is linked to endophthalmitis.